These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12914221)

  • 21. Mechanism for controlling the dimer-monomer switch and coupling dimerization to catalysis of the severe acute respiratory syndrome coronavirus 3C-like protease.
    Shi J; Sivaraman J; Song J
    J Virol; 2008 May; 82(9):4620-9. PubMed ID: 18305031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.
    Chen L; Gui C; Luo X; Yang Q; Günther S; Scandella E; Drosten C; Bai D; He X; Ludewig B; Chen J; Luo H; Yang Y; Yang Y; Zou J; Thiel V; Chen K; Shen J; Shen X; Jiang H
    J Virol; 2005 Jun; 79(11):7095-103. PubMed ID: 15890949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insight into the activity of SARS main protease: Molecular dynamics study of dimeric and monomeric form of enzyme.
    Zheng K; Ma G; Zhou J; Zen M; Zhao W; Jiang Y; Yu Q; Feng J
    Proteins; 2007 Feb; 66(2):467-79. PubMed ID: 17083088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. QM/QM studies for Michael reaction in coronavirus main protease (3CL Pro).
    Taranto AG; Carvalho P; Avery MA
    J Mol Graph Model; 2008 Oct; 27(3):275-85. PubMed ID: 18567519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: defining the extra domain as a new target for design of highly specific protease inhibitors.
    Shi J; Wei Z; Song J
    J Biol Chem; 2004 Jun; 279(23):24765-73. PubMed ID: 15037623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of the maturation process of SARS-CoV 3CL protease.
    Hsu MF; Kuo CJ; Chang KT; Chang HC; Chou CC; Ko TP; Shr HL; Chang GG; Wang AH; Liang PH
    J Biol Chem; 2005 Sep; 280(35):31257-66. PubMed ID: 15788388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three-dimensional model of a substrate-bound SARS chymotrypsin-like cysteine proteinase predicted by multiple molecular dynamics simulations: catalytic efficiency regulated by substrate binding.
    Pang YP
    Proteins; 2004 Dec; 57(4):747-57. PubMed ID: 15690493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Binding interaction of quercetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): structure-activity relationship studies reveal salient pharmacophore features.
    Chen L; Li J; Luo C; Liu H; Xu W; Chen G; Liew OW; Zhu W; Puah CM; Shen X; Jiang H
    Bioorg Med Chem; 2006 Dec; 14(24):8295-306. PubMed ID: 17046271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.
    Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD
    J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autoprocessing mechanism of severe acute respiratory syndrome coronavirus 3C-like protease (SARS-CoV 3CLpro) from its polyproteins.
    Muramatsu T; Kim YT; Nishii W; Terada T; Shirouzu M; Yokoyama S
    FEBS J; 2013 May; 280(9):2002-13. PubMed ID: 23452147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coronavirus 3CLpro proteinase cleavage sites: possible relevance to SARS virus pathology.
    Kiemer L; Lund O; Brunak S; Blom N
    BMC Bioinformatics; 2004 Jun; 5():72. PubMed ID: 15180906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of a non-prime site substituent and warheads combined with a decahydroisoquinolin scaffold as a SARS 3CL protease inhibitor.
    Ohnishi K; Hattori Y; Kobayashi K; Akaji K
    Bioorg Med Chem; 2019 Jan; 27(2):425-435. PubMed ID: 30558861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A mechanistic view of enzyme inhibition and peptide hydrolysis in the active site of the SARS-CoV 3C-like peptidase.
    Yin J; Niu C; Cherney MM; Zhang J; Huitema C; Eltis LD; Vederas JC; James MN
    J Mol Biol; 2007 Aug; 371(4):1060-74. PubMed ID: 17599357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The N-terminal octapeptide acts as a dimerization inhibitor of SARS coronavirus 3C-like proteinase.
    Wei P; Fan K; Chen H; Ma L; Huang C; Tan L; Xi D; Li C; Liu Y; Cao A; Lai L
    Biochem Biophys Res Commun; 2006 Jan; 339(3):865-72. PubMed ID: 16329994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor.
    Yang H; Yang M; Ding Y; Liu Y; Lou Z; Zhou Z; Sun L; Mo L; Ye S; Pang H; Gao GF; Anand K; Bartlam M; Hilgenfeld R; Rao Z
    Proc Natl Acad Sci U S A; 2003 Nov; 100(23):13190-5. PubMed ID: 14585926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris.
    Nguyen TT; Woo HJ; Kang HK; Nguyen VD; Kim YM; Kim DW; Ahn SA; Xia Y; Kim D
    Biotechnol Lett; 2012 May; 34(5):831-8. PubMed ID: 22350287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant.
    Akaji K; Konno H; Onozuka M; Makino A; Saito H; Nosaka K
    Bioorg Med Chem; 2008 Nov; 16(21):9400-8. PubMed ID: 18845442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enzymatic activity characterization of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer technique.
    Chen S; Chen LL; Luo HB; Sun T; Chen J; Ye F; Cai JH; Shen JK; Shen X; Jiang HL
    Acta Pharmacol Sin; 2005 Jan; 26(1):99-106. PubMed ID: 15659121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The catalysis of the SARS 3C-like protease is under extensive regulation by its extra domain.
    Shi J; Song J
    FEBS J; 2006 Mar; 273(5):1035-45. PubMed ID: 16478476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.
    Shie JJ; Fang JM; Kuo CJ; Kuo TH; Liang PH; Huang HJ; Yang WB; Lin CH; Chen JL; Wu YT; Wong CH
    J Med Chem; 2005 Jun; 48(13):4469-73. PubMed ID: 15974598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.